Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To assess long term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome

Next Previous
Trial Profile

To assess long term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 08 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Dravet syndrome; Epilepsy; Generalised seizures; Lennox-Gastaut syndrome; Myoclonic epilepsies; Seizures; Tonic-clonic epilepsy
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Acronyms CBD EAP

Most Recent Events

  • 01 Dec 2023 According to a Jazz Pharmaceuticals Plc media release, data from this study will be presented at the 2023 American Epilepsy Society (AES) annual meeting, being held December 1-5 in Orlando, Florida.
  • 29 Jul 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top